Core Viewpoint - The establishment of the China-ASEAN Regional Pharmaceutical Trading Platform marks a significant breakthrough in cross-border online transaction settlements for pharmaceutical companies, facilitating easier access for Chinese enterprises to ASEAN markets [1] Group 1: Platform Development - The platform is recognized as China's first cross-border regional pharmaceutical trading platform, successfully completing its first online cross-border transaction [1] - The platform serves as a "direct channel" for Chinese enterprises and procurement parties from ASEAN countries, providing comprehensive transaction services [1] Group 2: Company Participation - Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the first Chinese pharmaceutical company to complete a transaction through the platform, successfully supplying its product, Bailin capsules, to Singapore [1] - Currently, 114 leading Chinese pharmaceutical companies and 10 foreign pharmaceutical purchasers have joined the platform [1] Group 3: Future Prospects - The Guangxi Zhuang Autonomous Region aims to achieve breakthroughs in mutual recognition of pharmaceutical regulations with ASEAN countries through the platform [1] - The platform is expected to promote more "small and beautiful" pharmaceutical livelihood projects in the future [1]